Catherine Chia-yu Liu, OD | |
1585 3rd St, Fort Johnson, LA 71459-5102 | |
(337) 531-3277 | |
Not Available |
Full Name | Catherine Chia-yu Liu |
---|---|
Gender | Female |
Speciality | Optometrist |
Location | 1585 3rd St, Fort Johnson, Louisiana |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1376930610 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
152W00000X | Optometrist | 830 (Nevada) | Secondary |
152W00000X | Optometrist | 046011060 (Illinois) | Secondary |
152W00000X | Optometrist | 3390 (Colorado) | Primary |
Mailing Address | Practice Location Address |
---|---|
Catherine Chia-yu Liu, OD 1585 3rd St, Fort Johnson, LA 71459-5102 Ph: () - | Catherine Chia-yu Liu, OD 1585 3rd St, Fort Johnson, LA 71459-5102 Ph: (337) 531-3277 |
News Archive
One of the most widely prescribed drugs for acne vulgaris is benzoyl peroxide (BPO). However, at concentrations of 5-10%, BPO has the potential for skin irritation and dryness leading to poor patient compliance. Increasingly, BPO is combined with clindamycin in a fixed combination where the efficacy effects of the two ingredients are synergistic.
New detection methods could shorten the detection of sepsis from days down to only a few hours. Sepsis is a possibly mortal bacterial infection. It affects neonates and young infants more severely since their immune system is not fully developed. Now scientists are developing a fully automated system, which can identify sepsis in infants within hours instead of days.
Gentel Biosciences, a leader in proteomics tools, and Van Andel Research Institute, a biomedical research institute, jointly announce today the granting of U.S. Patent 7,838,634 for a new method to profile changes in the glycosylation of proteins captured on the surface of an antibody array slide. Gentel first obtained an exclusive right to commercialize the technology in 2006.
Researchers at the Johns Hopkins Kimmel Cancer Center have developed and tested a vaccine that triggered the growth of immune cell nodules within pancreatic tumors, essentially reprogramming these intractable cancers and potentially making them vulnerable to immune-based therapies.
› Verified 4 days ago